kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human BTLA (31-134) Protein, Fc Tag, 1mg  

Recombinant Human BTLA (31-134) Protein, Fc Tag, 1mg

Recombinant Human BTLA (31-134) Protein, Fc Tag (Human BTLA (31-134), Fc Tag) Lys 31 - Thr 134 was produced in human 293 cells (HEK293).

Synonym: recombinant, human, protein, BTLA,CD272

More details


Availability: within 7 days

1 800,00 €

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Recombinant Human BTLA, Fc Tag (BTA-H5255) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Thr 134 (Accession # NP_001078826.1).
Predicted N-terminus: Lys 31

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 38.7 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg of the Human BTLA (31-134), Fc Tag by the LAL method.

>92% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.


(1) Watanabe N., et al., 2003, Nat. Immunol. 4:670-679.
(2) Gavrieli M., et al., 2003, Biochem. Biophys. Res. Commun. 312:1236-1243.
(3) Sedy J.R., et al., 2005, Nat. Immunol. 6:90-98.